A recent review highlights the lack of proven targeted interventions for acute kidney injury (AKI) in critical care. While several therapies show potential, including intravenous amino acids and inorganic nitrates, no pharmacological treatment has been established for routine clinical use.
Background
Acute kidney injury (AKI) is a common and serious complication in critically ill patients, with incidence rates ranging from 20% to 75%. It is associated with significant morbidity, including chronic dialysis dependence and increased mortality. Current strategies primarily focus on preventing further deterioration of renal function, as no approved therapies exist for AKI treatment.
Data Highlights
Study
Intervention
AKI Incidence
PROTECTION trial
Intravenous balanced amino acids
27% vs 32% (placebo)
NITRATE-CIN trial
Oral inorganic nitrate
9% vs 31% (placebo)
Dexmedetomidine trial
Dexmedetomidine
18% vs 33% (placebo)
Another Dexmedetomidine trial
Dexmedetomidine
35% vs 50% (placebo)
Key Findings
Intravenous balanced amino acids reduced AKI incidence in cardiac surgery patients (27% vs 32% placebo).
Oral inorganic nitrate lowered contrast-induced AKI incidence in coronary angiography patients (9% vs 31% placebo).
Dexmedetomidine showed a reduced AKI risk in perioperative settings (18% vs 33% and 35% vs 50% in different trials).
Sodium-glucose cotransporter 2 inhibitors were associated with a 28% lower risk of AKI in chronic-use populations.
Angiotensin II was linked to lower mortality and more renal replacement therapy-free days in stage 3 AKI patients.
Device-based approaches like Cytosorb therapy showed variable outcomes in renal recovery.
Clinical Implications
The findings suggest that while certain interventions may reduce the incidence of AKI, their impact on long-term kidney function and survival remains unclear. Clinicians should remain cautious in interpreting these results and consider individual patient mechanisms of injury when evaluating treatment options.
Conclusion
The review underscores the complexity of AKI management in critical care, highlighting the need for further research to establish effective therapies.
Metabolomics analysis identified higher uric acid levels in patients with lipedema and lymphedema, although associations weakened following adjustment for renal insufficiency.
In a multicenter registry study, genetic diagnoses were associated with substantially lower cognitive, language, and motor scores; while birth weight, surgical timing, hospitalization burden, and caregiver education were also associated with outcomes.
